Bayer’s not breaking up. At least not yet
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: drug development
Where’s Lilly’s Alzheimer’s approval?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
Serum Institute of India wants government HPV contract
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Longer treatment gave better liver outcomes for MASH patients, Akero drug study shows
Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease…
Despite good data, Ironwood’s shares plummet
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Here are the cancer drugs Pfizer thinks could reignite investors’ interest
Pfizer spent more than four hours Thursday laying out its oncology program to investors. But…
The next act for a biotech rainmaker
Want to stay on top of the science and politics driving biotech today? Sign up to…
STAT+: Icon acquires HumanFirst to boost support for digital tools in clinical trials
As pharma companies wrestle with how and when to use wearables and other digital technologies…
STAT+: Biotech launches with $82 million for Parkinson’s cell therapy
The dream of being able to pluck a cell therapy off of a freezer shelf…
STAT+: Pfizer is about to make a big push in cancer. Will investors listen?
Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer…
Beam is trading like it’s 2021
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines
One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry. It was…
STAT+: Pharmalittle: We’re reading about Congress punts PBM reform, another obesity drug and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Obesity drug from Viking Therapeutics hits target in Phase 2 study, raising hopes for a competitor to existing medicines
An obesity medication from Viking Therapeutics succeeded in a Phase 2 clinical study, the company…
The FDA isn’t afraid to yank a disappointing drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Liver disease MASH is next target for obesity drugs in development
As drugmakers race to join the obesity drug market ignited by the approval of Wegovy…
What do CEOs owe the world?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Novavax’s money is going in the wrong direction
Want to stay on top of the science and politics driving biotech today? Sign up to get…
War zone or not, Ukraine seeks to reclaim its role as a hub for clinical trials
In the years leading up to Russia’s invasion, Ukraine had become a burgeoning hub of…
Actually Wegovy is good for dialysis companies, dialysis provider says
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Bayer, short on cash, reaches into shareholders’ pockets
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Alnylam thickened the plot
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Pharma’s contractors might finally be on the rebound
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Replicate’s srRNA rabies vaccine effective in Phase 1
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The need to know biotech news stories today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study
KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced…
Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability
The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate…
Psychedelic investment continues to ramp up
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Does Moderna’s RSV vaccine lose efficacy faster than others?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Gilead sours on the ‘don’t eat me’ business
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The GLP-1 panic is alive and well
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: AI can speed up drug discovery but don’t expect it to cure cancer, yet
David Reese calls it a “hinge moment” — the turning point when biotech and big…
Vertex still knows how to do what it does best
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Regeneron is interested in obesity treatments that combat muscle loss
Want to stay on top of the science and politics driving biotech today? Sign up to get…
A scholar of the patient ‘revolution’ tracks the arc from powerlessness to influence
At the end of each chapter in “Rebel Health: A Field Guide to the Patient-Led…
What makes a drug a blockbuster — or a cautionary tale?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Novavax is on thin ice, and the latest update isn’t exactly encouraging
Want to stay on top of the science and politics driving biotech today? Sign up to…
STAT+: Obscure vertigo drug could bring rare hope for patients with devastating neuron disease
About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo…
Pfizer’s reset year starts with a little profit
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts
Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that…
How an immunological Trojan horse could treat disease
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Vertex’s closely-watched pain relief drug succeeds in late-stage trials — with a catch
A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company…
23andMe breach targeted Chinese, Jewish populations
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Eli Lilly overtakes Tesla in market value
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Another step toward new drugs for Parkinson’s
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Lilly’s gene therapy restores hearing in an 11-year-old, paving way for more treatment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Ahead of Medicare drug price reform, pharma’s drug pricing has a Streisand effect
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Investigators fault Lilly plant for manufacturing issues
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The Senate health committee looks into its first subpoena in 40 years
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The XBI comedown after JPM
Want to stay on top of the science and politics driving biotech today? Sign up to get…